Novo Nordisk says an updated analysis of its REDEFINE 1 trial found that CagriSema is associated with average weight loss of about 25% in women. Seeking Alpha and Quartz both report results from a post-hoc review that focuses on women across different stages of menopause.

Quartz notes the findings span menopause stages, with average losses ranging from 23.1% to 26.7%. Seeking Alpha similarly highlights a roughly 25% figure, presenting it as a lead result for the drug in women. Both outlets frame the results as coming from an additional analysis rather than a primary endpoint from the original trial report. The outlets differ mainly in emphasis—one highlights the headline weight-loss percentage, while the other provides the stage-by-stage range—while describing the same overall outcome.